Table 3. Cohort Characteristics.
Data reported in brackets as mean standard deviation (SD) or as individual values where appropriate. NR—Not reported, PDD—Parkinson’s disease dementia, DLB—dementia with Lewy bodies, MMSE—Mini-mental State Exam score; ranges from 0—30 with higher scores indicative of better cognitive function, UPDRS—unified Parkinson’s disease rating scale (part I—mentation, II—Activities of daily living, III—motor).
| Citation | Number of participants | Average Age in years | Sex | Diagnosis | Time since diagnosis in years | MMSE /Cog scores | UPDRS | Hahn’s and Yohr stage | Co-morbid diseases/ conditions | Neuro-psychological medications | Weight/BMI | Residential Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rochester et al. 2009 | 9A | 75 (6) | M | PDD/PD-MCI | 6 (6)B | 22(3) | Part-III, 44(35.5–47.0) | 3 (2.5–3.0) | NR | NR | NR | Community |
| Ciro et al. 2013 | 1 | 73 | F | DLB | 2 | 12 | NR | 4 | Low back pain, hip arthritis, osteoporosis, heart palpitations | Rivastigmine, Citalopram, Rasagiline | NR | Community |
| Tabak et al 2013 | 1 | 61 | M | PDD | 0 C | 17 [MoCAD] | Part-I 11/16, Part-II 15/52 | NR | Deep brain stimulation, total knee replacement | Cardidopa- Levodopa | NR | Community |
| Dawley, 2014 | 1 | 57 | M | DLB | 1 | NR | NR | NR | None | Cardidopa /Levodopa, anti-depressant and anti-hallucinogenic medication | NR | Community |
| Telenius et al 2015 | 4 | 84 (10) | 3F, 1M | PDD | NR | 16 (7.1) | NR | NR | Average = 2 co-morbid | Average daily medications = 6.5 | NR | Nursing home |
A 5 participants indicative of dementia, remaining 4 have MCI,
B Time since diagnosis for Parkinson’s disease only,
C participant reported memory concerns 2 years prior, but seemed to have been diagnosed with dementia in the study,
D MoCA = The Montreal Cognitive Assessment was used; score ranges from 0–30 with higher scores indicative of better cognition.